Phillip A. Clendenin, the executive vice president of Amsurg, has sold 1,500 shares in the company at an average price of $43, according to a report by Ticker Report.
The entire transaction, legally disclosed in a filing with Securities & Exchange Commission, was a total of $64,500.
Piper Jaffray Cos. has also increased Amsurg's target price from $36 to $42. Analysts with Deutsche Bank have raised their target price for the company from $39 to $45.
More Articles on Transactions and Valuation Issues:
Medical Facilities Corporation Announces October Dividend
What to Consider Before Selling an ASC
Key Observations on ASC Transactions in 2013
The entire transaction, legally disclosed in a filing with Securities & Exchange Commission, was a total of $64,500.
Piper Jaffray Cos. has also increased Amsurg's target price from $36 to $42. Analysts with Deutsche Bank have raised their target price for the company from $39 to $45.
More Articles on Transactions and Valuation Issues:
Medical Facilities Corporation Announces October Dividend
What to Consider Before Selling an ASC
Key Observations on ASC Transactions in 2013